Idea Pharma has boosted its medical investigation team with the appointment of Partha Ghosh and Peter Wootton.
Former AstraZeneca’s medical affairs scientist Wootton and Ghosh, who was previously a director at Parexel, add clinical and regulatory design expertise to the phase II strategy consultants.
Prior to joining Idea Pharma, Wootton (pictured) spend two and a half years at AstraZeneca specialising first in neuroscience and more recently in diabetes. Before that he worked at Grunenthal UK in scientific liaison and advisory roles.
He said: “Time after time I have seen great molecules fail within pharma because they all seem to follow the same formulaic processes and fixate on the obvious paths to market … no two molecules are the same and therefore they need to be treated differently! The obvious path is not always the right path. This is where Idea is different!”
Meanwhile, Ghosh’s previous roles include serving as a principal consultant within Parexel’s consulting arm.
Commenting on his appointment Ghosh said: “The industry faces its toughest challenge to date. Changing the way it works and ultimately how it thinks is no easy task, yet Idea Pharma is one company that is making serious waves.
“They have been on my radar for a number of years now as a company that is injecting innovation and creativity into early stage molecule/product development. I am keen to work alongside the Idea team and the new breed of clients that they seem to attract, ones that fully understand what it means to be truly innovative.”